Recent Posts

• The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity
• The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.
• From Patent Risk to Strategic Clarity: How Docana Built an IP Strategy with PatentVest
• Using AI In Your Inventive Process? Proceed to Patent, But Carefully
• The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine